BioVie to present design of Phase 2 SUNRISE-PD trial

BioVie (BIVI) announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson’s Disease and Related Disorders, being held May 7-10, 2025, in New York City. As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committee. If the trial’s results are positive, participants may be eligible to enter a longer-term, open-label safety study.